0000899243-20-030759.txt : 20201110 0000899243-20-030759.hdr.sgml : 20201110 20201110211708 ACCESSION NUMBER: 0000899243-20-030759 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201109 FILED AS OF DATE: 20201110 DATE AS OF CHANGE: 20201110 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Snodgres Jon CENTRAL INDEX KEY: 0001613498 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-14656 FILM NUMBER: 201302780 MAIL ADDRESS: STREET 1: REPLIGEN CORPORATION, 41 SEYON STREET STREET 2: BUILDING #1, SUITE 100 CITY: WALTHAM STATE: MA ZIP: 02435 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: REPLIGEN CORP CENTRAL INDEX KEY: 0000730272 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 042729386 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 41 SEYON STREET STREET 2: BUILDING 1, SUITE 100 CITY: WALTHAM STATE: MA ZIP: 02453 BUSINESS PHONE: 7814499560 MAIL ADDRESS: STREET 1: 41 SEYON STREET STREET 2: BUILDING 1, SUITE 100 CITY: WALTHAM STATE: MA ZIP: 02453 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-11-09 0 0000730272 REPLIGEN CORP RGEN 0001613498 Snodgres Jon C/O REPLIGEN CORPORATION 41 SEYON ST., BLDG 1, STE 100 WALTHAM MA 02453 0 1 0 0 Chief Financial Officer Common Stock 2020-11-09 4 S 0 705 194.69 D 31562 D Common Stock 2020-11-09 4 M 0 1893 59.52 A 33455 D Common Stock 2020-11-10 4 M 0 3086 32.40 A 36541 D Common Stock 2020-11-10 4 S 0 3086 193.00 D 33455 D Stock Option (Right to Buy) 59.52 2020-11-09 4 M 0 1893 0.00 D 2029-02-28 Common Stock 1893 3788 D Stock Option (Right to Buy) 32.40 2020-11-10 4 M 0 3086 0.00 D 2027-02-23 Common Stock 3086 0 D $194.69 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $194.56 to $194.89, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Shares vest and become exercisable as follows: 1,894 shares on 2/28/2021 and 1,894 shares on 2/28/2022. This option is currently exercisable. /s/ Jeffrey P. Leduc (Attorney in Fact) 2020-11-10